Barron's Pharma Stock Takeover List

The cover story from this weekend’s Barron’s was about the inevitability of the next wave of Big Pharma takeovers.

Many of the stocks mentioned have been on their own for way longer than is necessary.  There’s no reason for one- or two-drug pharma companies to remain independent, depriving themselves of the chance for serious sales and marketing behind their compounds.

Andrew Bary put together a list of 13 smaller drug makers that could and perhaps should get bought.  Some of the names you’ll probably recognize like Dendreon ($DNDN) and Human Genome ($HGSI).  Others will be interesting stories for you to learn about, like Cubist ($CBST) and Onyx ($ONXX).

I’ve never been a big biotech or small pharma investor, I’ve seen more disappointment than success from watching my colleagues blow themselves up in this arena when the “guaranteed” FDA ruling or clinical trial went the wrong way.  But I do get involved here and there and this seems like a nice list to use as a starting point for my own homework.


Doctor in the House (Barron’s)

This content, which contains security-related opinions and/or information, is provided for informational purposes only and should not be relied upon in any manner as professional advice, or an endorsement of any practices, products or services. There can be no guarantees or assurances that the views expressed here will be applicable for any particular facts or circumstances, and should not be relied upon in any manner. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment.

The commentary in this “post” (including any related blog, podcasts, videos, and social media) reflects the personal opinions, viewpoints, and analyses of the Ritholtz Wealth Management employees providing such comments, and should not be regarded the views of Ritholtz Wealth Management LLC. or its respective affiliates or as a description of advisory services provided by Ritholtz Wealth Management or performance returns of any Ritholtz Wealth Management Investments client.

References to any securities or digital assets, or performance data, are for illustrative purposes only and do not constitute an investment recommendation or offer to provide investment advisory services. Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others.

Wealthcast Media, an affiliate of Ritholtz Wealth Management, receives payment from various entities for advertisements in affiliated podcasts, blogs and emails. Inclusion of such advertisements does not constitute or imply endorsement, sponsorship or recommendation thereof, or any affiliation therewith, by the Content Creator or by Ritholtz Wealth Management or any of its employees. Investments in securities involve the risk of loss. For additional advertisement disclaimers see here:

Please see disclosures here.

What's been said:

Discussions found on the web
  1. PI News Wire commented on Sep 22

    … [Trackback]

    […] Read More Information here on that Topic: […]

  2. commented on Sep 28

    … [Trackback]

    […] Information on that Topic: […]

  3. Test Automation and RPA commented on Nov 12

    … [Trackback]

    […] Info to that Topic: […]

  4. imitation perfect knockoff rolex commented on Nov 16

    … [Trackback]

    […] Find More here to that Topic: […]

  5. luxury amethyst wig up to 50 off commented on Dec 08

    … [Trackback]

    […] Information to that Topic: […]

  6. Azure DevOps commented on Dec 09

    … [Trackback]

    […] Here you will find 67039 more Info to that Topic: […]

  7. rolex replica commented on Dec 21

    … [Trackback]

    […] Read More Info here on that Topic: […]